Variables | Disease-free survival | Overall survival | ||
---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
Univariate analysis | ||||
Sex (Male/Female) | 1.5 (0.7–3.5) | 0.236 | 1.7 (0.9–3.5) | 0.178 |
Age (≤60/>60) | 0.8 (0.4–2.6) | 0.421 | 1.4 (0.9–3.6) | 0.279 |
Histological diagnosis (Head and Body PC/Tail PC) | 1.8 (0.9–3.9) | 0.145 | 1.5 (0.6–3.4) | 0.243 |
Clinical stages (I+II/III+IV) | 2.8 (1.4–5.9) | 0.018 | 3.2 (0.9–6.7) | <0.01 |
Tumor differentiation (Poor and Moderate/High) | 1.2 (0.3–3.7) | 0.231 | 1.8 (0.5–4.4) | 0.137 |
Tumor size (≤4 cm/>4 cm ) | 1.8 (0.8–4.1) | 0.165 | 2.2 (1.2–4.2) | 0.089 |
LNM (Negative/Positive) | 3.9 (1.1–8.6) | <0.01 | 4.5 (1.5–8.7) | <0.01 |
Liver metastasis (Negative/Positive) | 3.5 (1.5–6.4) | <0.01 | 4.1 (1.6–8.5) | <0.01 |
CA199(U/ml) (≤1000/ >1000) | 2.4 (0.7–4.3) | 0.059 | 2.0 (0.6–4.8) | 0.107 |
KPS (≤80/>80) | 1.9 (0.5–4.8) | 0.156 | 2.3 (0.8–4.7) | 0.119 |
CD44v6 mRNA (Low/High) | 3.1 (1.2–6.4) | 0.017 | 2.9 (1.4–6.8) | 0.033 |
Integrin-β1 mRNA (Low/High) | 2.7 (1.3–6.3) | 0.034 | 3.2 (1.5–6.8) | 0.025 |
CD44v6 protein (Low/High) | 3.2 (1.1–7.1) | 0.012 | 3.9 (1.2–7.5) | <0.01 |
integrin-β1 protein (Low/High) | 2.7 (0.8–6.7) | 0.045 | 3.0 (1.1–6.2) | 0.013 |
Multivariate analysis | ||||
Clinical stages (I+II/III+IV) | 3.5 (0.9–7.5) | <0.01 | 3.6 (1.1–7.1) | <0.01 |
LNM (Negative/Positive) | 2.8 (0.6–7.2) | 0.033 | 3.2 (1.0–6.9) | 0.021 |
Liver metastasis(Negative/Positive) | 3.3 (0.7–6.8) | 0.015 | 3.5 (1.2–7.5) | <0.01 |
CD44v6 mRNA (Low/High) | 2.9 (1.2–6.5) | 0.028 | 2.9 (1.4–6.8) | 0.033 |
Integrin-β1 mRNA (Low/High) | 2.4 (0.6–6.7) | 0.096 | 3.2 (1.1–7.2) | 0.019 |
CD44v6 protein (Low/High) | 3.3 (1.3–7.8) | 0.010 | 3.7 (1.3–7.5) | <0.01 |
Integrin-β1 protein (Low/High) | 2.5 (0.7–6.8) | 0.067 | 3.2 (1.2–6.7) | 0.016 |